Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.51 |
| ▸ | CYP2A13 | Q16696 | 4/20 | 0.50 |
| ▸ | NCF1 | P14598 | 1/20 | 0.50 |
| ▸ | NOS3 | P29474 | 1/20 | 0.49 |
| ▸ | NOS1 | P29475 | 1/20 | 0.49 |
| ▸ | NOS2 | P35228 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.47 |
| ▸ | EPAS1 | Q99814 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7568331 | 0.98 | HRH3 (0.63) | HRH3SMN1; SMN2ALDH1A1LMNAMAPT | |
| SCHEMBL27778712 | 0.93 | HRH3 (0.58) | HRH3SMN1; SMN2ALDH1A1LMNAMAPT | |
| SCHEMBL7530239 | 0.91 | HRH3 (0.58) | HRH3SMN1; SMN2ALDH1A1LMNAMAPT | |
| SCHEMBL3133899 | 0.89 | HRH3 (0.79) | HRH3SMN1; SMN2ALDH1A1LMNAMAPT | |
| SCHEMBL15467001 | 0.85 | HRH3 (0.87) | HRH3SMN1; SMN2ALDH1A1LMNAMAPT | |
| SCHEMBL8721655 | 0.85 | HRH3 (0.57) | HRH3SMN1; SMN2ALDH1A1LMNAMAPT | |
| Water SCHEMBL1702298 | 0.82 | SIGMAR1 (0.68) | HRH3SMN1; SMN2ALDH1A1LMNACYP2A13 | |
| SCHEMBL738784 | 0.81 | HRH3 (0.67) | HRH3SMN1; SMN2ALDH1A1NCF1CXCR4 | |
| SCHEMBL7356340 | 0.81 | HRH3 (0.60) | HRH3SMN1; SMN2ALDH1A1NCF1MEN1 | |
| SCHEMBL422200 | 0.81 | SIGMAR1 (0.56) | HRH3KCNJ1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 957 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192657-A1 | 1,2,4-TRIAZOLINONE CB1 INHIBITORS | GFB (ABC), LLC | 2023-06-22 | — | — | US | claimed |
| WO-2023070120-A1 | KETOAMIDES FOR TREATING MALIGNANCY | BIOTHERYX, INC. (US) | 2023-04-27 | — | — | WO | claimed |
| EP-4114838-A1 | 1,2,4-TRIAZOLINONE CB1 INHIBITORS | Goldfinch Bio, Inc. (US) | 2023-01-11 | — | — | EP | claimed |
| US-20220389009-A1 | SUBSTITUTED 1,6-NAPHTHYRIDINE INHIBITORS OF CDK5 | GFB (ABC), LLC | 2022-12-08 | — | — | US | claimed |
| CN-114787160-A | Imidazopyridazines and imidazopyridines as activin receptor-like kinase-2 inhibitors | 因赛特公司 | 2022-07-22 | — | — | CN | claimed |
| CN-114761000-A | Substituted 1, 6-naphthyridine inhibitors of CDK5 | 金翅雀生物公司 | 2022-07-15 | — | — | CN | claimed |
| US-11345712-B2 | Protein-targeting compounds and pharmaceutical compositions thereof, and their therapeutic applications | BIOTHERYX, INC. (US) | 2022-05-31 | — | — | US | claimed |
| WO-2022011274-A1 | SUBSTITUTED 1,6-NAPHTHYRIDINE INHIBITORS OF CDK5 | GOLDFINCH BIO, INC. (US) | 2022-01-13 | — | — | WO | claimed |
| EP-3740493-B1 | INHIBTEURS DE L'INDOLEAMINE 2,3-DIOXYGÉNASE ET/OU DU TRYPTOPHANE DIOXYGÉNASE | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-12-01 | — | — | EP | claimed |
| EP-3898627-A1 | IMIDAZOPYRIDAZINE AND IMIDAZOPYRIDINE COMPOUNDS AS INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE-2 | Incyte Corporation (US) | 2021-10-27 | — | — | EP | claimed |
| US-5726302-A | SUBSTITUTED 4-AMINO PYRROLO(2,3-D) PYRIMIDINE AND PYRAZOLO(3,4-D) PYRIMIDINE NUCLEOSIDE ANALOGS | GENSIA INC. (US) | 1998-03-10 | — | — | US | claimed |
| EP-0790239-A1 | Novel 4-phenyl-2-(piperazinyl/perhydrodiazepinyl/aminoalkyl)carbonylmethyl)-1,4-dihydropyridine-3,5-dicarboxylic acid derivatives as bradykinin receptor antagonists | PFIZER INC. (US) | 1997-08-20 | — | — | EP | claimed |
| WO-1997022619-A2 | INHIBITORS OF INTERLEUKIN-1β CONVERTING ENZYME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1997-06-26 | — | — | WO | claimed |
| WO-1996040707-A1 | WATER-SOLUBLE ADENOSINE KINASE INHIBITORS | GENSIA SICOR (US) | 1996-12-19 | — | — | WO | claimed |
| US-5496901-A | SOLUBILIZING MONOMER IN A CARBON DIOXIDE FLUID SOLVENT AND POLYMERIZING | UNIVERSITY OF NORTH CAROLINA (US) | 1996-03-05 | — | — | US | claimed |
| EP-0666851-A4 | SUBSTITUTED PHTHALAZINONES AS NEROTENSIN ANTAGONISTS. | — | 1995-08-30 | — | — | EP | claimed |
| EP-0666851-A1 | SUBSTITUTED PHTHALAZINONES AS NEROTENSIN ANTAGONISTS | MERCK & CO. INC. (US) | 1995-08-16 | — | — | EP | claimed |
| EP-0638095-A1 | METHOD OF MAKING FLUOROPOLYMERS | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 1995-02-15 | — | — | EP | claimed |
| WO-1994010151-A1 | SUBSTITUTED PHTHALAZINONES AS NEROTENSIN ANTAGONISTS | MERCK & CO., INC. (US) | 1994-05-11 | — | — | WO | claimed |
| WO-1993020116-A1 | METHOD OF MAKING FLUOROPOLYMERS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 1993-10-14 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220389009-A1 | SUBSTITUTED 1,6-NAPHTHYRIDINE INHIBITORS OF CDK5 | CDK5, CDK5R1, PKD1 | HRH3 4071/4885SMN1; SMN2 2901/4885ALDH1A1 2375/4885 |
| US-11345712-B2 | Protein-targeting compounds and pharmaceutical compositions thereof, and their therapeutic applications | HSP90B1, EIF4EBP1, SERPINA6 | HRH3 4130/4885SMN1; SMN2 536/4885ALDH1A1 4668/4885 |
| US-20230192657-A1 | 1,2,4-TRIAZOLINONE CB1 INHIBITORS | CNR1, GPR119, CNR2 | HRH3 1095/4885SMN1; SMN2 3645/4885ALDH1A1 736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.